Apollomics, Inc.

Equities

APLM

KYG0411D1079

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 11:20:43 2024-05-09 am EDT			5-day change	1st Jan Change
0.3999 ^USD	-3.22%		-2.46%	-58.56%

May. 08	Apollomics, Inc. Appoints Robert Lin to the Board of Directors	CI
May. 08	Apollomics, Inc. announced that it has received $5.75 million in funding	CI

Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023

September 28, 2023 at 05:00 pm EDT

Apollomics, Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was USD 150.69 million compared to USD 3.42 million a year ago. Basic loss per share from continuing operations was USD 2.55 compared to USD 0.12 a year ago.

Diluted loss per share from continuing operations was USD 2.55 compared to USD 0.68 a year ago.

Latest news about Apollomics, Inc.

Apollomics, Inc. Appoints Robert Lin to the Board of Directors	May. 08	CI
Apollomics, Inc. announced that it has received $5.75 million in funding	May. 07	CI
Apollomics, Inc. announced that it expects to receive $5.75 million in funding	May. 05	CI
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene	Apr. 25	CI
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer	Apr. 05	CI
EF Hutton Cuts Price Target on Apollomics to $6.50 From $11, Maintains Buy Rating	Apr. 01	MT
HC Wainwright Adjusts Apollomics' Price Target to $5 From $17, Maintains Buy Rating	Apr. 01	MT
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Apollomics, Inc. Appoints Matthew Plunkett as Chief Financial Officer	Mar. 04	CI
Apollomics Gets Nasdaq Noncompliance Notice	Jan. 19	MT
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	Jan. 03	CI
Top Premarket Gainers	Nov. 27	MT
Apollomics Announces Two New Cohorts in Global Phase 2 Sparta Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with Met Dysregulation	23-10-31	CI
Sector Update: Health Care Stocks Slip in Late Afternoon	23-10-27	MT
Sector Update: Health Care	23-10-27	MT
Apollomics Shares Soar on Experimental Drug's Efficacy in Brain Tumor Patient	23-10-27	MT
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast	23-10-27	MT
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports	23-10-27	MT
Top Premarket Gainers	23-10-27	MT
Apollomics Inc. Announces Report of Activity of Vebrelinib in Glioblastoma Multiforme with PTPRZ-MET Fusion	23-10-26	CI
Apollomics Inc. Announces Efficacy of Vebrelinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate of 75%	23-10-23	CI
Apollomics, Inc. Announces Presentations of Vebreltinib Data at ESMO 2023	23-10-16	CI
HC Wainwright Adjusts Price Target on Apollomics to $17 From $18, Maintains Buy Rating	23-10-03	MT
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
EF Hutton Assumes Apollomics at Buy With $25 Price Target	23-08-23	MT

Chart Apollomics, Inc.

Duration

Period

More charts

Company Profile

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies. The Company uses both targeted, immuno-oncology, and other approaches to address a range of cancer indications, such as acute myeloid leukemia, lung cancer, brain cancer, and other solid tumors. The product candidates in its pipeline are categorized into three groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumour inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Its advanced product candidate is vebreltinib (APL-101), a potent, oral active, highly selective c-Met inhibitor. Its anti-cancer enhancer product candidates include uproleselan (APL-106) and are antagonists of a cell adhesion receptor called E-selectin. Its immuno-oncology product candidates consist of APL-501, APL-502, APL-801 and APL-810. Its other product candidates include APL-122, APL-102, and APL-108.

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Apollomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4132 USD

Average target price

5.75 USD

Spread / Average Target

+1,291.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
APOLLOMICS, INC.	-58.56%	36.98M
VERTEX PHARMACEUTICALS INCORPORATED	+2.53%	108B
REGENERON PHARMACEUTICALS, INC.	+9.67%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-11.33%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-7.41%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.29%	13.99B
SAREPTA THERAPEUTICS, INC.	+34.95%	12.53B

Bio Therapeutic Drugs